Data-modelling and visualisation in chronic kidney disease (CKD): a step towards personalized medicine

Introduction:
Decision making in the context of the ten-minute consultation can be challenging, and the advent of personalized medicine might make the task even more complex. The concept of personalized medicine had been born out of a combination of: Improvements in our knowledge about the human genome; understanding of biomarkers and other developments in basic science; and advances in computational power. 1 Personalized medicine is generally described as the dividing patients into groups on the basis of their biological or genomic make-up; and personalizing management regimes for these groups. However, as clinicians we sit with individual patients and need to develop individual strategies for every patient, and have some insight into whether they are getting better or getting worse with often very few biochemical measures at our disposal; and, although our computerized medical record systems may hold a decade or more of readily available data; 2,3 though it is not necessarily easy to interpret. . Visualising longitudinal patient data may help their clinician observe the interplay between markers of disease and therapy on an individual patient basis. Longitudinal data held in electronic patient records may provide insight into whether people are responsive or not to therapy.
Chronic kidney disease is an important condition which affects between 5%-10% of the population; 4 and interventions which can affect outcome, particularly strict control of systolic BP, 5 can be implemented in primary care It is important because it is associated with an increased risk of major cardiovascular events and death; broadly similar to the excess mortality and morbidity associated with diabetes. 6 There is clear guidance how to manage CKD in the adult population, 7, 8 However, GPs find the guidance challenging to implement, 9 and lack confidence in managing CKD compared with other comorbidities. 10 Difficulties include that renal function primarily measured using estimated glomerular filtration rate (eGFR) fluctuates markedly; this because it is derived from serum creatinine, primarily a product of muscle breakdown and protein containing food, The national guidance for management of CKD in adults suggests that a decline in eGFR of >5ml/min in one year or a decline of >10ml/min in 5 years should be regarded as rapid decline and referred for specialist care. Data from the Quality Improvement in Chronic Kidney Disease (QICKD) trial 11 suggests that the decline seen year on year in the population in eGFR is between 0.4-0.7ml/min per year. Figure 1 shows the decline in eGFR during adult life and superimposed are the rates of decline where referral is recommended.
Figure 1:
The rate of decline in eGFR with increasing age for males, females and the Population; superimposed are triangles to represent accelerated decline where referral is recommended. From QICKD study baseline data (circa. 50,000 people with CKD).
However, looking at the population as a whole there is considerable fluctuation in creatinine, with much of this fluctuation exceeding the decline in eGFR of >5ml/min in one year or >10ml/min in 5 years recommended as thresholds for referral. 12 For example, in the QICKD trial we found that 31% (16,587/53,322) people with two eGFR readings more than a year apart had their creatinine fluctuate by over 5ml/min in one year (Fig 2) ; clearly it would not have been feasible to refer them all. Fluctuation between minimum and maximum eGFR over one and five years; the vertical bold lines indicate a decline of over 5 and 10 ml/min in eGFR, which should be referred to specialist care
Unfortunately combining our knowledge about the population trend and how eGFR fluctuates in the population does not help greatly with the management of individual patients. In the clinical scenario the responsible clinician has to decide whether the change in eGFR is part of normal fluctuation or not for the individual patient in front of them. We carried out this pilot study to show whether we could use visualisation techniques to display trends in renal function in individual patients; and indicate whether a new value is part of normal fluctuation or an abnormal finding.
Method:
The aim of the pilot is to demonstrate methods of data visualisation to display; (1) Fluctuation among individual patients within population with apparently smooth change; and (2) Create pilot outputs from routine data that can be used to help manage individual patients; using methods which can be readily made machine processable. Longitudinal displays of routine data have been proposes as a method that might help to improve care. 13 We worked with a small panel of clinical experts in CKD, nephrologists, researchers and general practitioners to understand how improved display of data might improve clinical management.
The expert panel confirmed the need for a data-presentation methodology that is personalised and patient-centred. We have set out in the introduction how current methodologies, based on analysis at the population level are not adequate because the trend in each patient is aggregated; the methodological challenge is to produce an improved version.
We transferred techniques developed from biometrics to medical science because both domains share the following similarities: They deal with signals generated from biology processes; Both types of data can be 1D, 2D, 3D or 3D+time; Both type of data are longitudinal in nature, often extending over many years; The types of data samples are collected in open environments, or "in-vivo", that is, the experimenter has minimal control over the experimental setting. The last characteristic makes the data modelling problem extremely challenging.
The biometric methods applied to the data modelling problem in CKD are as follows: (1) Estimate the biometric performance over time -in the case of CKD we applied this approach to eGFR as the key measure of renal function; 14 (2) The model parameters: primarily how eGFR fluctuates with age, is calibrated using a regression model that hypothesises what is acceptable change over time; 15 ( 3) The method produces an output to at the individual patient level which might ultimately be capable of supporting improved medical decision making; 16 (4) The method that handles missing values in data modelling 17 ; (5) A method that models a hypothesis (person identity) taking contextual covariates into account 18 The assumption in the method is that that the biomedical signal is generated by a steady process that is corrupted by daily biologically induced fluctuation and other activities unaccounted for (collectively considered as "noise"). Creatinine production is known to be generated by muscle breakdown and its serum level is related to muscle mass; the steady process. Generally as renal function declines blood levels of creatinine rise; again a steady process of creatinine rising and eGFR falling with increasing age (Fig 1) . However, there are a number of factors which can cause creatinine to change; and create "noise," or fluctuation. Eating protein based meals and increased cell breakdown (due to illness or treatments for cancer) can increase serum creatinine (SCr); and eating little and reducing muscle mass (e.g. an amputation) can reduce it. eGFR is related to the inverse of serum creatinine (SCr), so as SCr rises with deteriorating renal function so eGFR falls.
The data for the QICKD trial are held on a secure MySQL 19 database. Customised data extraction queries were developed to provide test variables for this exercise. These queries mimic those that might be used to extract data from live clinical systems rather than from a research database.
We fitted a regression line to the eGFR values available on a per patient basis, and for the entire population. This regression line has the effect of smoothing the "noise" or fluctuation in eGFR. The regression line also enables 95% confidence intervals to be plotted, giving some indication for that individual patient whether their fluctuation is within an acceptable limit based on previous change or potentially greater. We plotted fitted regression curves, superimposed with the original data, for a random selection of 20 patients with over 15 years data.
We then developed a data display data for an individual patient with CKD, and diabetes. We displayed: (1) eGFR as a measure of renal function; (2) Glycated haemoglobin (HbA1c) -a measure of the quality of diabetes control (using International Federation of Clinical Chemists (IFCC) unitsthe nearer to 55 mmol/mol the better the control); (3) Body mass index (BMI) -a measure of obesity (Weight in Kg/Height in metres squared -BMI over 30kg/m 2 defines obesity; (4) Blood pressure (BP) -measures as systolic and diastolic (a BP of under 130/80 is recommended); 7 (5) Prescribed of Metformin -this is a first line anti-diabetic drug -which is useful because it helps reduce appetite but has been associated with impaired renal function; 20 (6) Prescribed other oral anti-diabetic drugs (OAD) -these drugs are effective in controlling diabetes, but by lowering blood glucose and increase appetite and result in weight gain; (7) We also plotted the consumption of aspirin, as an example of a cardiovascular medication.
We plotted a regression line and 95% confidence intervals for the variation in eGFR, HbA1c, and BMI. We initially attempted this with BP but it involved the display of too many lines. We plotted drug consumption on a consumption of tablets or item per 28 days. We weighted up the pros and cons of using a medicines possession ratio, as we have previously used for osteoporosis medication; 21 however as we may not always know the intended dose of medication we considered that the number of tablets or items per 28 days would be of most value.
Ethical considerations: The QICKD Trial is ethically approved and this study, details are recorded at the International Standard Randomised Controlled Trial Number Register ( ISRCTN56023731).
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Results:
We display how beneath the smooth and linear decline in eGFR (Fig 1) there is considerable noise/fluctuation among individuals. The fitted regression curves, are superimposed with the original data, for 20 patients, are shown in Figure 3 . For example: on the extreme right of the figure is a person where we have data from the patients late 80s, through to aged nearly 100 years old. During this period the patients "smoothed" eGFR rises from 42ml/min to 56ml/min. However, their fluctuating eGFR changes from 48ml/min down to its lowest level 39ml/min eventually finishing at 58ml/min. For this individual, although their trend overall was one of improvement might have been referred on the basis of their rapidly declining eGFR. We presented this figure and these to a panel of CKD experts; they thought this approach offered more than comparing individuals with the population trend ( Figure 1 ). They felt that the smoothed data made it much easier to observe trends in patients. They reported data presented in the way the potential to enable an estimate to be made of the annual rate of change of eGFR in an individual. They speculated if that could be based on their smoothed regression line, and whether this more accurately than represented their underlying change in renal function. They felt that individual case examination "must" be superior to the current approach which is to compare an individual's change with arbitrarily set limits which define an accelerated decline (i.e. >5ml/min on one year, >10ml/min in 5 years). We developed a viewer for an individual patient data. This data visualisation displays anonymised, real patient data for one patient drawn from the QICKD trial. This is shown as an exemplar or how machine processable data might be displayed (Figure 4) . In this single patient we display data for the patient between age 63 and 81 years old, 18 years data. There is only four years eGFR data, but this shows an initial decline then levelling off in that decline. Glycated haemoglobin (HbA1c) has risen steadily between age 70 and 78 years, but has plateaued and moved back towards target values over the last 3 to 4 years. The improvement in HbA1c appears to be mirrored by a change in BMI, a fall in BMI appears to be associated with a fall in HbA1c. Systolic BP generally appears to have been higher in the last decade The step up on BP is associated with the when metformin was first prescribed, which in turn may have been associated with a diagnosis of diabetes. One short period on an OAD was associated with a fall in HbA1c, however the association between falling HbA1c and BMI appears stronger.
Initial opinion from our panel was generally positive. They felt this type of computer generated display might significantly improve care in complex cases. They thought that the change in BMI and HbA1c may have been hard to discern in usual care records, some of which allow listing or graphing of variables but not as many variables, nor as succinctly. No existing providers they were aware of provide regression lines to illustrate the trend, or confidence intervals to give some idea if a value is an outlier. However, they also thought that considerable testing was needed of the combinations of variables needed for effective management. For example, should proteinuria measures always be displayed with eGFR; haemoglobin with aspirin, other anticoagulants, and non-steroidal antiinflammatory drugs; the need to display blood pressure medications, maybe angiotensin modulating drugs separately; and others.
Discussion:
Principal findings:
We have successfully demonstrated that routine data in UK practice had significant amounts of longitudinal data. We have also shown that smooth trends in eGFR at the population level are not matched by changes in at the individual patient level. Additionally, many patients have changes in eGFR which exceed the national guidance definition of "rapidly declining" eGFR. Finally, we have created a computer generated visual display of a range of variables and fitted curves (Fig 4) ; which was well received by a small panel.
Implications of the findings:
Longitudinal data is uniquely and readily available in primary care and other computer systems and can be harnessed to improve individual patient care. eGFR is a "noisy" variable with a great deal of fluctuation. So many people appear to exceed the definition of "rapidly declining" eGFR that we think this requires review. This early pilot suggests that if they can be shown to be valid, that trend lines and confidence intervals of the sort we have displayed may be of great value to clinicians in managing individual patients.
Comparison with the literature:
We have already reported issues with creatinine fluctuation at the population level and these individual patient trends are compatible with this.
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Much of the important literature about the rationale for visualisation has been reviewed by Samal et al., and this work is entirely compatible with their position paper. 13 Personalize medicine is likely to be here to stay and this initiative may provide pointers towards how we can observe key data. Similar approaches have been proposed in cancer management. 23 In developing this intervention further we will need to follow advice and best practice on how to develop a new complex intervention. 24 There are some similarities in this approach and those adopted in in statistical process control (SPC) 25, 26 -though statistical process control proposes methods for observing data and does not encompass the potentially automated methods of data extraction which form part of this method.
Limitations of the method:
There are many limitations to this pilot. We don't know if our assumptions about the underlying trends are correct, or whether our confidence intervals are valid. We have not optimised the list of variables we display. These data have been extracted from a research database which is completely under our control rather than involving live data extraction from a computerised medical record system. Most importantly no studies have yet been carried out, either simulated or in clinical practice, suggesting that this approach improves patient care.
Call for further research:
It should be possible to develop modelling software capable of analysing and modelling NHSextracted data with time-varying covariates and factors, as well as other contextual factors including economic deprivation and life style. The software can be used by researchers in medical informatics, biomedical science and primary care doctors, giving an overview of the known history of a patient. This represents a major change considering that a typical piece of software in primary-care practices provides only snapshot views of a patient divided into different tabs of measurements and prescriptions, thus failing to give an overall longitudinal picture of the patient's history compared with those generated here (Fig 4) . Such tools might be used to distinguish patients with chronic kidney disease (CKD) who are more likely to progress to have complications and more serious illness from those who are less likely. There may also be potential to quantify the impact of known and new associations with progression.
Conclusions:
This study is a small first step towards the generation of visualisation and modelling tools that can model longitudinal data on a personal basis. There is potential for this to be used to offer more personalized care. However, there are many stages needed first, to develop and test a complex intervention. eGFR is a noisy variable with considerable fluctuation, current definitions of "rapid decline" as a threshold for referral appear incorrect. Computer generated visualisation of longitudinal data may provide a mechanism for improving care. The rate of decline in eGFR with increasing age for males, females and the Population; superimposed are triangles to represent accelerated decline where referral is recommended. From QICKD study baseline data (n= 50,331, people with CKD).
Figure 2:
Fluctuation between minimum and maximum eGFR over one and five years; the vertical bold lines indicate a decline of over 5 and 10 ml/min in eGFR, which should be referred to specialist care 
